Ranbaxy Laboratories Ltd, the country's top drugmaker by sales, reported a quarterly loss of Rs 2,983 crore, mainly due to a provision related to a probe by the US Justice Department.
The company said it set aside Rs 2,648 crore as a provision towards settlement of the probe related to compliance issues at the drugmaker's manufacturing facilities in the United States and India.
Ranbaxy, majority owned by Japan's Daiichi Sankyo Co, said consolidated net sales soared 79.2% in the December quarter at Rs 3,738 crore.
Valued at $3.85 billion, shares in Ranbaxy fell 21.2% in October-December when the benchmark healthcare index was little changed.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app